Fund Introduction

 

Novo Nordisk Haemophilia Research Fund in China is based on a sponsorship agreement between Novo Nordisk, a biopharmaceutical company headquartered in Denmark (www.novonordisk.com), and Shanghai Centre for Translational Medicine. The objective of the Fund is to fund or co-fund research based activities of common interest within the field of haemophilia and/or related disciplines or technologies at institutions affiliated to the Ministry of Health and other academic institutions in China and to enhance the understanding and cooperation between these research communities and Novo Nordisk.

Copyright:  Novo Nordisk Haemophilia Research Fund in China

Technical support: Shanghai Yi Chao